Huntington Disease – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Huntington Disease – Pipeline Review, H2 2019’, provides an overview of the Huntington Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Huntington Disease

– The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects

– The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Huntington Disease”

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Huntington Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Active Biotech AB

AcuraStem Inc

Addex Therapeutics Ltd

Adeptio Pharmaceuticals Ltd

AFFiRiS AG

Alkermes Plc

Allianz Pharmascience Ltd

Alsonex Pty Ltd

Anima Biotech Inc

Annexon Inc

Armgo Pharma Inc

ArunA Biomedical Inc

Asklepios BioPharmaceutical Inc

Avergen Pharmaceuticals GmbH

Azevan Pharmaceuticals Inc

BrainStorm Cell Therapeutics Inc

Brainvectis SAS

BridgeBio Pharma Inc

Celon Pharma SA

Chaperone Therapeutics Inc

Chong Kun Dang Pharmaceutical Corp

Cleave Therapeutics Inc

Collaborative Medicinal Development LLC

Curyx Bio Inc

DanPET AB

Dystrogen Therapeutics SA

Emerald Health Sciences Inc

Evotec SE

Exicure Inc

F. Hoffmann-La Roche Ltd

Genervon Biopharmaceuticals LLC

Hope Biosciences LLC

Immungenetics AG

Krisani Bio Sciences Pvt Ltd

Living Cell Technologies Ltd

Locana Inc

Medesis Pharma SA

MindImmune Therapeutics Inc

Mitochon Pharmaceuticals Inc

Mitoconix Bio Ltd

Mitokinin LLC

MMJ International Holdings Corp

Navitor Pharmaceuticals Inc

NeuBase Therapeutics Inc

NeuExcell Therapeutics Inc

Neurimmune Holding AG

Neurodon LLC

NeuroNascent Inc

New World Laboratories Inc

NLS Pharma Group

Novartis AG

Nuredis Inc

Omeros Corp

Ophidion Inc

Oryzon Genomics SA

Oscine Therapeutics

Oxalys Pharmaceuticals Inc

PharmatrophiX Inc

Priavoid GmbH

Primary Peptides Inc

ProQR Therapeutics NV

Prous Institute for Biomedical Research SA

PTC Therapeutics Inc

reMYND NV

Resilio Therapeutics LLC

Retrotope Inc

Sage Therapeutics Inc

Secura Bio Inc

Seneb BioSciences Inc

Shinkei Therapeutics LLC

SOM Biotech SL

Sosei Heptares

Spark Therapeutics Inc

Stealth BioTherapeutics Corp

T3D Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Thelial Technologies SA

TreeFrog Therapeutics SAS

Ultragenyx Pharmaceutical Inc

UniQure NV

Vaccinex Inc

Vitality Biopharma Inc

Vivoryon Therapeutics AG

Voyager Therapeutics Inc

Vybion Inc

Wave Life Sciences Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Huntington Disease Overview 6

Huntington Disease Therapeutics Development 7

Huntington Disease Therapeutics Assessment 20

Huntington Disease Companies Involved in Therapeutics Development 30

Huntington Disease Drug Profiles 51

Huntington Disease Dormant Projects 254

Huntington Disease Discontinued Products 261

Huntington Disease Product Development Milestones 262

Appendix 272

List of Tables

“List of Tables

Number of Products under Development for Huntington Disease, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Huntington Disease – Pipeline by Active Biotech AB, H2 2019

Huntington Disease – Dormant Projects, H2 2019

Huntington Disease – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports